<DOC>
	<DOCNO>NCT01243372</DOCNO>
	<brief_summary>RATIONALE : Studying sample tissue laboratory patient receive cetuximab may help doctor understand predict well patient respond treatment . PURPOSE : This research study study biomarkers predict response cetuximab patient advance colorectal cancer .</brief_summary>
	<brief_title>Biomarkers Predicting Response Cetuximab Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine , among patient advanced CRC , whether effect treatment ( cetuximab v bevacizumab ) progression-free survival ( PFS ) depend tumor BRAF V600E mutational status . Secondary - To study relationship tumor BRAF V600E mutational status , OS , tumor response . OUTLINE : This multicenter study . Previously collect formalin-fixed paraffin-embedded baseline tumor sample analyze BRAF V600E mutation . Mutation status correlate clinical response outcome data patient enrol CALGB-C80405 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Participation CALGBC80405 Have KRAS WT KRAS mut tumor Randomized treatment either bevacizumab cetuximab alone Patients randomized combination therapy eligible Available specimen PCO BRAF mutation detection Patient consent use sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IIIA colon cancer</keyword>
	<keyword>stage IIIB colon cancer</keyword>
	<keyword>stage IIIC colon cancer</keyword>
	<keyword>stage IVA colon cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>